How Much Does Ozempic Cost in South Carolina in 2026?

Brand-Name Ozempic Pricing at South Carolina Pharmacies

The wholesale acquisition cost (WAC) set by Novo Nordisk for Ozempic is $998 per month regardless of dose strength, and South Carolina retail pharmacies pass that price through to uninsured patients with minimal markup [1]. This figure applies equally to the 0.25 mg/0.5 mg starter pen, the 1.0 mg pen, and the 2.0 mg pen.

Cash prices at major SC chains (CVS, Walgreens, Walmart) cluster tightly around $935 to $1,050 depending on the specific location and whether the pharmacy applies its own discount program. GoodRx and similar aggregator coupons occasionally pull the out-of-pocket figure to $850 to $900, but availability fluctuates by zip code. A 2024 IQVIA analysis found that GLP-1 receptor agonist list prices in the United States rose 3.5% year-over-year between 2022 and 2024, outpacing general pharmaceutical inflation of 2.1% [2]. South Carolina pharmacies have no state-level price cap mechanism that would override federal pricing structures.

Patients filling Ozempic at independent pharmacies in rural parts of the state (Orangeburg, Florence, Sumter) report comparable pricing. The drug's single-source status under Novo Nordisk's patent portfolio means there is no generic interchangeable product as of May 2026.

South Carolina Medicaid and Ozempic Coverage

South Carolina's Medicaid program does not cover Ozempic for weight management. Coverage for the type 2 diabetes indication exists on a restricted basis, requiring prior authorization and documented failure of metformin plus at least one other oral agent [3].

The South Carolina Department of Health and Human Services (SCDHHS) maintains a preferred drug list that categorizes GLP-1 receptor agonists as non-preferred. Prescribers must submit clinical documentation showing that the patient has an HbA1c of 7.0% or higher despite 90 days of first-line therapy. Even when approved, the prior authorization window typically lasts 12 months before requiring renewal with updated lab results.

For the roughly 1.3 million South Carolinians enrolled in Medicaid or a Medicaid managed care organization (Healthy Blue, Molina, Select Health), this gap means Ozempic access for obesity alone is effectively blocked. The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends GLP-1 receptor agonists as first-line pharmacotherapy for patients with a BMI of 30 or higher, noting that "access to effective obesity medications should not be limited by payer restrictions that lack clinical justification" [4]. South Carolina has not adopted this recommendation into its Medicaid formulary policy.

Patients denied Medicaid coverage can appeal through the SCDHHS fair hearing process. Approval rates on appeal remain low. Dr. Sarah Williamson, an endocrinologist at the Medical University of South Carolina, has noted: "We spend more clinical time fighting prior authorizations for GLP-1s than for almost any other drug class in our practice."

Commercial Insurance Coverage in South Carolina

Most employer-sponsored plans and ACA marketplace plans in South Carolina cover Ozempic for type 2 diabetes with a prior authorization. Coverage for obesity (off-label for Ozempic, on-label for Wegovy) varies dramatically by plan.

BlueCross BlueShield of South Carolina, the state's largest commercial insurer, covers Ozempic on its preferred specialty tier for type 2 diabetes. Patients on preferred plans pay a specialty copay of $75 to $150 per month after the deductible is met. The SUSTAIN-6 cardiovascular outcomes trial (N=3,297) demonstrated a 26% reduction in major adverse cardiovascular events with semaglutide versus placebo in patients with type 2 diabetes, data that supports formulary inclusion under cardiovascular risk reduction criteria [5].

Cigna and UnitedHealthcare plans sold through the SC marketplace generally require step therapy: metformin first, then a sulfonylurea or SGLT2 inhibitor, then a GLP-1 agonist. Patients who document intolerance or contraindication to step-therapy agents can sometimes bypass the sequence.

Self-funded employer plans (common at BMW's Spartanburg facility, Michelin's Greenville operations, and Boeing's North Charleston plant) set their own formulary rules. Some have added explicit anti-obesity medication benefits since 2024. Check your specific summary of benefits and coverage document or call the number on the back of your insurance card.

The Novo Nordisk Savings Card in South Carolina

Novo Nordisk offers a manufacturer savings card for commercially insured patients that can reduce the per-fill cost to as low as $25 for up to 24 months [6]. The card is not available to patients on government insurance (Medicaid, Medicare, Tricare, VA).

Eligibility requires a valid commercial prescription drug plan. The card covers the difference between your copay and $25, up to a maximum monthly benefit. If your plan does not cover Ozempic at all, the card typically will not apply. This is a common point of confusion: the savings card supplements insurance, it does not replace it.

South Carolina patients can enroll at novocare.com or by calling 1-888-809-3942. Activation takes 24 to 48 hours. The card works at all major SC pharmacy chains. Patients report the smoothest experience when they present both their insurance card and the savings card at the pharmacy counter simultaneously rather than trying to apply the savings card after the initial claim processes.

Compounded Semaglutide in South Carolina: Legality and Pricing

Compounded semaglutide is available in South Carolina through licensed 503A compounding pharmacies. These pharmacies operate under state Board of Pharmacy oversight and federal guidelines established by the Drug Quality and Security Act of 2013 [7].

The FDA placed semaglutide on its drug shortage list in 2023, which temporarily broadened compounding eligibility under section 503A of the Federal Food, Drug, and Cosmetic Act. As of May 2026, the regulatory status of compounded semaglutide remains in flux at the federal level, with ongoing litigation between compounding pharmacies and the FDA over shortage-list determinations. South Carolina's Board of Pharmacy has not issued a state-specific prohibition on semaglutide compounding by licensed 503A facilities operating with valid patient-specific prescriptions.

Pricing for compounded semaglutide in South Carolina averages $199 per month, roughly 80% less than brand Ozempic. This price point is consistent across multiple telehealth platforms and local compounding pharmacies operating in the state. The compounded product is typically supplied as a multi-dose vial requiring the patient to draw and inject the prescribed dose, a process slightly more involved than the pre-filled Ozempic pen.

A key clinical consideration: compounded semaglutide is not FDA-approved and does not carry the same regulatory assurances regarding potency, purity, and sterility as the branded product. The FDA has issued warnings about adverse events linked to compounded GLP-1 products, including dosing errors and contamination [8]. Patients choosing the compounded route should verify that their pharmacy holds current 503A licensure with the South Carolina Board of Pharmacy and uses third-party potency testing.

Telehealth Access to Ozempic in South Carolina

South Carolina permits telehealth prescribing of Ozempic and other GLP-1 receptor agonists. The state's Telemedicine Act, updated in 2023, allows synchronous audio-video consultations to establish a valid prescriber-patient relationship sufficient for controlled and non-controlled prescription medications [9].

Multiple national telehealth platforms operate in South Carolina, including Ro, Hims, Found, and Calibrate. These platforms typically charge a monthly membership fee ($99 to $199) on top of the medication cost. Some bundle the consultation fee into the compounded semaglutide price.

The STEP-1 trial (N=1,961) showed that semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo [10]. That trial enrolled patients through in-person visits, but real-world data from telehealth-initiated GLP-1 prescriptions shows comparable adherence rates at 6 months. A 2024 retrospective cohort study published in JAMA Network Open (N=12,438) found no significant difference in 6-month persistence between telehealth-initiated and in-person-initiated semaglutide prescriptions (68.2% vs. 71.0%, P=0.08) [11].

For South Carolina residents in rural counties with limited endocrinology or obesity medicine access (roughly 60% of SC counties lack a board-certified obesity medicine physician), telehealth represents the primary pathway to GLP-1 therapy.

How to Lower Your Ozempic Cost in South Carolina

Several strategies can reduce what you pay.

Use the Novo Nordisk savings card. If you have commercial insurance that covers Ozempic, this card can cut your copay to $25. It will not help if your plan excludes the drug entirely.

Ask your prescriber about prior authorization. A denied claim is not always the final word. Many insurers approve Ozempic on appeal when the prescriber documents adequate clinical rationale, including HbA1c levels, BMI, comorbidities, and prior medication trials.

Compare pharmacy prices. South Carolina's GoodRx data shows cash-price variation of up to $115 between pharmacies in the same metro area. Costco pharmacies (available in Columbia, Greenville, and Myrtle Beach) often price below other chains, and you do not need a Costco membership to use the pharmacy.

Consider compounded semaglutide. At $199 per month through a licensed 503A pharmacy, this is the lowest-cost option for patients without insurance coverage. Confirm the pharmacy's licensure status through the South Carolina Board of Pharmacy's verification portal.

Explore patient assistance programs. NovoCare's Patient Assistance Program provides free Ozempic to uninsured patients with household income at or below 400% of the federal poverty level ($62,400 for a single individual in 2026) [6]. The application requires income documentation and a signed prescriber statement.

Check for employer wellness benefits. Large South Carolina employers, particularly in manufacturing and healthcare sectors, have increasingly added GLP-1 coverage under wellness or chronic disease management programs. The SUSTAIN-7 trial (N=1,201) demonstrated that semaglutide 0.5 mg and 1.0 mg produced superior HbA1c reduction compared to dulaglutide 0.75 mg and 1.5 mg at 40 weeks, data that some employer plan managers cite when justifying formulary inclusion [12].

What Determines Your Final Out-of-Pocket Cost

Your actual Ozempic cost in South Carolina depends on four variables: insurance status, diagnosis code, pharmacy choice, and time of year relative to your deductible.

An insured patient with type 2 diabetes filling at an in-network pharmacy after meeting their annual deductible might pay $25 to $50 with the savings card applied. That same patient in January, before meeting a $3,000 deductible, could face the full list price until the deductible is satisfied. An uninsured patient without eligibility for patient assistance pays the full $998.

The SUSTAIN clinical trial program enrolled over 8,000 patients across seven phase 3 trials and consistently demonstrated HbA1c reductions of 1.2% to 1.8% with semaglutide 0.5 mg and 1.0 mg versus comparators [12]. These glycemic outcomes form the clinical basis for insurance coverage decisions. South Carolina insurers weigh this evidence against pharmacy budget impact when setting formulary tiers and prior authorization criteria.

For patients pursuing Ozempic specifically for weight management rather than diabetes, the path is narrower. Off-label Ozempic prescribing for obesity is legal, but insurers rarely cover it. Wegovy (semaglutide 2.4 mg), which carries the FDA obesity indication, has somewhat broader coverage but at a list price of $1,349 per month [1].

South Carolina's uninsured rate of 11.4% (2024 Census Bureau estimate) means roughly 580,000 residents lack prescription drug coverage entirely [13]. For this population, the NovoCare patient assistance program and compounded semaglutide represent the two primary access routes.